Resolution of immune checkpoint inhibitors-induced inflammatory arthritis while maintaining active treatment with checkpoint inhibitors and after its discontinuation: An observational study
Alexandra Ladouceur(Centre Hospitalier Universitaire de Bordeaux), Marie Kostine(Hôpital Cardiologique du Haut-Lévêque), Marine Gross‐Goupil(Centre Hospitalier Universitaire de Bordeaux), M. Zysman(Centre Hospitalier Universitaire de Bordeaux), Marie‐Elise Truchetet(Centre National de la Recherche Scientifique), Baptiste Sionneau, Félix Lefort(Centre Hospitalier Universitaire de Bordeaux), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Christophe Richez(Boston University), Charlotte Domblides, Rémi Veillon(Centre Hospitalier Universitaire de Bordeaux), Thomas Barnetche(Université de Bordeaux), Thierry Schaeverbeke(Inserm), E. Gérard(Université de Bordeaux), Amaury Daste(Centre Hospitalier Universitaire de Bordeaux), M. Beylot‐Barry, Anne Pham‐Ledard(Peter MacCallum Cancer Centre), S. Prey(Centre Hospitalier Universitaire de Bordeaux)
Cited by 5
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k